Short answer
Bio-Techne (TECH) filed an 8-K current report with the SEC on August 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Exhibit 99.1 contains Bio-Techne’s results for quarter and year ended June 30, 2026.
Bio-Techne 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Exhibit 99.1 contains Bio-Techne’s results for quarter and year ended June 30, 2026
- Press release covers financial condition as of June 30, 2026
- Results are furnished under Item 2.02, limiting Section 18 liability and incorporation by reference absent specific filing reference
Item 8.01 · Other Events
- Cash dividend announcement by Bio-Techne, signaling a shareholder capital-return action
- Dividend details and record/payment dates contained in Exhibit 99.2
Item EX-99.1 · Exhibit EX-99.1
- Q4 revenue $321.2M, up 1% reported and 3% organic, signaling modest underlying demand improvement
- Adjusted EPS $0.52 versus $0.53, while adjusted operating margin expanded to 32.2% from 32.0%
- Diagnostics and Spatial Biology organic revenue grew 8%, with segment margin rising to 11.2% from 6.0%
- Protein Sciences margin declined to 42.0% from 43.6% on unfavorable volume and product mix
- Merck KGaA acquisition progressing at $73 per share cash, implying approximately $11.3B enterprise value
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Bio-Techne 8-K filings
Get the next TECH 8-K as it lands
Follow TECH for push alerts, or ask the research agent what this filing means.